Evolving novel pathogen pandemic Severity, extent, trajectory, and duration of the pandemic is unknown |
-
•
Risk of healthcare-associated, community-acquired or donor-derived infection
-
•
Potential adverse psychosocial effects due to heightened infection control measures for recipients (eg, social distancing, prolonged isolation)
|
-
•
Risk of healthcare-associated (eg, dialysis center) or community-acquired infection
-
•
Adverse medical and psychosocial effects from prolonged dialysis (eg, recurrent dialysis access-related complications)
-
•
Loss of access to transplantation may be prolonged, with risk of exclusion from transplantation due to disease progression or death
-
•
Poorer posttransplant outcomes with prolonged duration on dialysis
|
| Impact of COVID-19 in different population groups (eg, transplant vs dialysis patients) |
|
|
| Treatment and prophylaxis options not established |
-
•
Therapeutics for trial purposes or compassionate use may exclude transplant patients
-
•
Risk of drug-drug interaction, especially with immunosuppressants
-
•
Reduction of immunosuppression to manage infection may put the graft at risk
|
|
| Impact on healthcare resources |
-
•
Access to resources needed for transplantation may be disrupted
-
•
Transplant processes may compete for critical healthcare resources (eg, staff, medical supplies, and facilities) essential for pandemic response
|
|
| Risks to donor/caregivers |
|
|